Brought to you by 
PDL licenses cancer antibody to igeneon
19 Nov 2002
Executive Summary
Cancer immunotherapy company igeneon exercised its option under an agreement signed in 2000 with Protein Design Labs (humanized antibodies to treat disease) to exclusively license worldwide development and marketing rights to the anticancer candidate, HuABL364 (now called IGN311).
Deal Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PDL licenses cancer antibody to igeneon
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice